Payment overview · 2025
General Payments
$1,897.25
110 reported records · 20 companies
Healthcare provider profile · identity verified
Joanne Langton, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · MORRISTOWN, TN · NPI 1255375465
Verified facts
What the public records show
CMS Open Payments records show Joanne Langton, MD received $1,897.25 in general payments during 2025 across 110 reported records.
Lilly USA, LLC accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 375 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 451 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 584 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $337.34 | 17.8% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.35 | 11.0% | 11 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $204.09 | 10.8% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $159.60 | 8.4% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $159.24 | 8.4% | 7 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $135.82 | 7.2% | 15 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $135.62 | 7.2% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $100.39 | 5.3% | 5 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $89.00 | 4.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.46 | 4.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.43 | 2.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.59 | 2.8% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $45.22 | 2.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.69 | 1.4% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $24.10 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.73 | 1.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.87 | 0.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $16.00 | 0.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.43 | 0.8% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $14.28 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,897.25 | 110 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $279.73 | 21 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $208.35 | 11 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $204.09 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $159.60 | 9 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $159.24 | 7 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $135.82 | 15 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $135.62 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.04 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $112.04 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $100.39 | 5 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $89.00 | 4 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $63.98 | 3 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $53.59 | 3 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $45.22 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $26.69 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 375 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 451 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 584 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
307 | 73 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
375 | 82 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
375 | 82 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
451 | 80 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
119 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
584 | 112 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1503 | 363 |
| Ozempic | Semaglutide | 584 | 112 |
| Gabapentin | Gabapentin | 452 | 64 |
| Mounjaro | Tirzepatide | 451 | 80 |
| Jardiance | Empagliflozin | 375 | 82 |
| Liothyronine Sodium | Liothyronine Sodium | 319 | 81 |
| Synthroid | Levothyroxine Sodium | 307 | 73 |
| Metformin Hcl | Metformin Hcl | 298 | 81 |
| Methimazole | Methimazole | 274 | 63 |
| Humalog | Insulin Lispro | 256 | 55 |
| Metformin Hcl Er | Metformin Hcl | 240 | 61 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 239 | 68 |
| Novolog | Insulin Aspart | 225 | 55 |
| Glimepiride | Glimepiride | 224 | 61 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 207 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 194 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 180 | 37 |
| Novolog Flexpen | Insulin Aspart | 163 | 50 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 160 | 29 |
| Pregabalin | Pregabalin | 158 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 152 | 42 |
| Tresiba Flextouch U-200 | Insulin Degludec | 149 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 142 | 36 |
| Alprazolam | Alprazolam | 135 | 17 |
| Glyxambi | Empagliflozin/Linagliptin | 131 | 23 |
| Lisinopril | Lisinopril | 127 | 33 |
| Insulin Lispro | Insulin Lispro | 123 | 39 |
| Trulicity | Dulaglutide | 119 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 108 | 42 |
| Januvia | Sitagliptin Phosphate | 102 | 20 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 100 | 23 |
| Testosterone Cypionate | Testosterone Cypionate | 99 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 93 | 31 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 11 |
| Omeprazole | Omeprazole | 83 | 21 |
| Tramadol Hcl | Tramadol Hcl | 76 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 67 | suppressed |
| Diazepam | Diazepam | 66 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 66 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | 16 |
| Potassium Chloride | Potassium Chloride | 64 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Hydrocortisone | Hydrocortisone | 55 | 13 |
| Levemir Flexpen | Insulin Detemir | 54 | 15 |
| Lorazepam | Lorazepam | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 50 | 16 |
| Farxiga | Dapagliflozin Propanediol | 49 | 11 |
| Furosemide | Furosemide | 49 | 11 |
| Glipizide | Glipizide | 49 | 17 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 49 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 14 |
| Tradjenta | Linagliptin | 48 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 47 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 46 | 20 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Simvastatin | Simvastatin | 44 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 41 | 11 |
| Rybelsus | Semaglutide | 41 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 40 | suppressed |
| Lovastatin | Lovastatin | 39 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Estradiol | Estradiol | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 34 | 13 |
| Sertraline Hcl | Sertraline Hcl | 34 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Armour Thyroid | Thyroid,pork | 31 | suppressed |
| Comfort Ez Insulin Syringe | Syringe And Needle,insulin,1ml | 30 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Testosterone | Testosterone | 30 | suppressed |
| Fluconazole | Fluconazole | 27 | 14 |
| Allopurinol | Allopurinol | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 26 | suppressed |
| Prednisone | Prednisone | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 24 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 24 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 24 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 19 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 19 | suppressed |
| Omnitrope | Somatropin | 19 | suppressed |
| Propylthiouracil | Propylthiouracil | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Insulin Aspart | Insulin Aspart | 17 | suppressed |
| Jatenzo | Testosterone Undecanoate | 17 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 17 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 13 | 13 |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Combipatch | Estradiol/Norethindrone Acet | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,897.25 · 110 records | Lilly USA, LLC | AREXVY, CRENESSITY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, JARDIANCE, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NP Thyroid 60, Omnipod, Ozempic, PROLIA, SHINGRIX, TEPEZZA, TWIIST, UNITHROID, XYOSTED, Yorvipath, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error